

RE-CLASSIFICATION OF SALTS OF "ETRYPTAMINE (INN)"

<b>Name of product</b>	<b>Classification</b>
Etryptamine (INN)	2939.79
Etryptamine acetate	2939.79
Etryptamine hydrochloride	2939.79

**Amendments to INN Lists 12, 70, 87, 93 and 98**

RE-CLASSIFICATION OF CERTAIN CHEMICAL PRODUCTS

<b>Product name</b>	<b>Classification</b>
Rivanicline (INN List 93)	2939.79
Omacetaxine mepesuccinate (INN List 98)	2939.79
Ilepcimide (INN List 70)	2939.79
Trabectedin (INN List 87)	2939.80
Psilocybine (INN List 12)	2939.80

**Amendment to INN List 118**

CHEMICAL TO BE RECLASSIFIED

<b>Product</b>	<b>Classification</b>
Zilucoplan (INN LIST 118)	2933.79

**INN LIST 120, Classification in HS 2017 edition**

<b>INN</b>	<b>Classification (HS 2017)</b>
abrocitinib	2935.90
aclimostat	2934.99
adlinacogene civaparvovec	3002.90
afizagabar	2934.99
aldafermin	2937.19
amcipatricin	2941.90
aspacytarabine	2934.99
atoltivimab	3002.13
avanbulin	2934.99
avexitide	2937.19
baloramotide	3002.20
balstilimab	3002.13
bedinvetmab	3002.13
bermekimab	3002.13
berotralstat	2933.19
blarcamesine	2932.19
cadalimogene ixalentevec	3002.90
cendakimab	3002.13
cetuximab sarotalocan	3002.13
choriogonadotropin beta	2937.19
cinpanemab	3002.13
clascoterone	2937.29
clervonafusp alfa	3507.90
cobolimab	3002.13
crinecerfont	2934.10
crisdesalazine	2922.50
cytisinicline	2939.79
danicamtiv	2934.99
devafidugene civaparvovec	3002.90
devimistat	2930.90
disitamab	3002.13
disitamab vedotin	3002.13

<b>INN</b>	<b>Classification (HS 2017)</b>
donanemab	3002.13
dubermatinib	2935.90
efaprinermin alfa	3002.13
efgivanermin alfa	3002.13
elipovimab	3002.13
envafolimab	3002.13
esafoxolaner	2934.99
etokimab	3002.13
etranacogene dezaparvovec	3002.90
fadaltran	2934.99
fisogatinib	2934.99
foscarbidopa	2928.00
foslevodopa	2922.50
fuzapladib	2935.90
garadacimab	3002.13
garetosmab	3002.13
glenzocimab	3002.13
gusacitinib	2933.59
ieramilimab	3002.13
inbakicept	3002.13
inlezifigene civaparvovec	3002.90
inodiftagene vixteplasmid	2934.99
islatravir	2934.99
lacutamab	3002.13
lademirsén	2934.99
lapretolimod	2932.99
lerociclib	2933.59
levilimab	3002.13
lorukafusp alfa	3002.13
maftivimab	3002.13
magrolimab	3002.13
mocemestrocel	3002.90
motixafortide	2934.99
nanatinostat	2933.59
naxitamab	3002.13

<b>INN</b>	<b>Classification (HS 2017)</b>
nidanilimab	3002.13
nimacimab	3002.13
olutasidenib	2933.79
pabinafusp alfa	3507.90
pecavaptan	2933.99
pegbelfermin	2937.19
pegloprastide	3907.20
pepinemab	3002.13
pizuglanstat	2934.99
plamotamab	3002.13
pozelimab	3002.13
pralsetinib	2933.59
pravibismane	2934.99
quetmolimab	3002.13
ranuzifigene civaparvovec	3002.90
relfovetmab	3002.13
repotrectinib	2934.99
resamirigene bilparvovec	3002.90
risuteganib	2933.99
rovotocogene durparvovec	3002.90
rozibafusp alfa	3002.13
runcaciguat	2924.29
selgantolimod	2933.59
selitrectinib	2933.59
selpercatinib	2933.59
semorinemab	3002.13
serclutamab	3002.13
serclutamab talirine	3002.13
serdexmethylphenidate	2933.39
setanaxib	2933.79
sibofimloc	2934.99
simurosertib	2934.99
sonlicromanol	2934.99
taminadenant	2933.59
tamrintamab	3002.13

INN	Classification (HS 2017)
tamrintamab pamozirine	3002.13
tanfanercept	3002.13
teclistamab	3002.13
tefidsogene civaparvovec	3002.90
telitacicept	3002.13
tidutamab	3002.13
tilavonemab	3002.13
tomaralimab	3002.13
triheptanoïn	2915.90
troriluzole	2934.20
tuvatexib	2933.49
vibecotamab	3002.13
vimirogant	2933.39
vipivotide tetraxetan	2933.99
vofatamab	3002.13
volagidemab	3002.13
volrubigene ralaparvovec	3002.90
voluloride	2933.99
zalifrelimab	3002.13
ziresovir	2934.99
ziritaxestat	2934.10
zotatifin	2934.99
zuranolone	2933.19

**Reclassification of INN products in HS 2022 edition (applicable as of 1.1.2022)**

RECLASSIFICATION (HS 2022) OF INN PRODUCTS (INN LIST 120)

INN	Classification (HS 2022 edition)
baloramotide	3002.41
pegloprastide	3907.29
mocemestrocel	3002.51

**INN LIST 121, Classification in HS 2017 edition**

<b>INN</b>	<b>Classification (HS 2017)</b>
arlipoic acid	2934.99
actinium ( <sup>225</sup> Ac) lintuzumab satetraxetan	2844.40
amivantamab	3002.13
anetumab corixetan	3002.13
arpraziquantel	2933.59
astegolimab	3002.13
atleradstrocel	3002.90
avalotcagene ontaparvovec	3002.90
avdoralimab	3002.13
avizakimab	3002.13
axatilimab	3002.13
bamocafort	2935.90
batoclimab	3002.13
befovacimab	3002.13
benufutamab	3002.13
betibeglogene autotemcel	3002.90
branebrutinib	2933.39
brensocatib	2934.99
brepocitinib	2933.59
catequentinib	2933.49
centhaquine	2933.59
cinrebafusp alfa	3002.13
cosibelimab	3002.13
dirloctocogene samoparvovec	3002.90
dovanvetmab	3002.13
efbemalenograstim alfa	3002.13
efmitemant alfa	3002.13
elexacafort	2935.90
elivaldogene autotemcel	3002.90
elsubrutinib	2933.39
enavogliflozin	2932.99
encelimab	3002.13

<b>INN</b>	<b>Classification (HS 2017)</b>
enmetazobactam	2934.99
epcoritamab	3002.13
ezaladcigene resoparvovec	3002.90
fadraciclib	2933.59
felcisetrag	2933.39
felezonexor	2933.39
ferric bepectate	3505.10
fianlimab	3002.13
firzotemcel	3002.90
flubrobenguane ( <sup>18</sup> F)	2844.40
fosdenopterin	2934.99
gatralimab	3002.13
giroctocogene fitelparvovec	3002.90
glofitamab	3002.13
gontivimab	3002.13
gremubamab	3002.13
imifoplatin	2843.90
innopitant	2933.59
ivaltinostat	2928.00
ivuxolimab	3002.13
izencitinib	2933.39
lenacapavir	2935.90
letetresgene autoleucel	3002.90
linperlisib	2935.90
lodapolimab	3002.13
lomardexamfetamine	2925.29
lonodelestat	2933.79
manelimab	3002.13
mavezelimab	3002.13
mesdopetam	2930.90
mevociclib	2933.59
mezagitamab	3002.13
milategrast	2933.59
mipetresgene autoleucel	3002.90
mirzotamab	3002.13

<b>INN</b>	<b>Classification (HS 2017)</b>
mirzotamab clezutoclast	3002.13
mobocertinib	2933.59
monomethyl fumarate	2917.19
narsoplimab	3002.13
navafenterol	2934.99
navocafort	2934.99
nelonemdaz	2922.50
nerindocianine	2933.99
nogapendekin alfa	3002.13
numidargistat	2933.99
nurulimab	3002.13
obafistat	2935.90
odesivimab	3002.13
odronextamab	3002.13
olafertinib	2933.59
olitresgene autoleucel	3002.90
olpasiran	2934.99
omidubicel	3002.90
onvansertib	2933.59
orismilast	2934.99
otemaproksesul	2930.90
pacmilimab	3002.13
paltusotine	2933.49
pamufetinib	2933.49
patritumab deruxtecan	3002.13
paxalisib	2934.99
petosemtamab	3002.13
pimitespi	2933.29
praluzatamab	3002.13
praluzatamab ravtansine	3002.13
pregabalin arenacarbil	2924.19
ralmitaront	2934.99
rebamipide mofetil	2934.99
remestemcel	3002.90
remibrutinib	2933.59



<b>INN</b>	<b>Classification (HS 2017)</b>
retifanlimab	3002.13
rilzabrutinib	2934.99
rimtuzalcap	2934.99
ritlecitinib	2933.59
ropocamptide	2933.99
rovaleucel	3002.90
samotolisib	2933.39
sasanlimab	3002.13
sepfarsen	2934.99
serplulimab	3002.13
setamevetcel	3002.90
simlukafusp alfa	3002.13
sinbaglustat	2933.39
sonelokimab	3002.13
sovateptide	2937.19
stapuldencel	3002.90
suvodirsen	2934.99
tafolecimab	3002.13
talquetamab	3002.13
tanimilast	2935.90
tapotoclax	2934.99
tebrocabtagene autoleucel	3002.90
tilvestamab	3002.13
tinlarebant	2933.39
tinurilimab	3002.13
toludesvenlafaxine	2922.50
tominersen	2934.99
trazpiroben	2933.39
treprostinil palmitil	2937.50
velsecorat	2934.99
veverimer	3911.90
vibostolimab	3002.13
vupanorsen	2934.99
xiliertinib	2933.59
zagotenemab	3002.13

<b>INN</b>	<b>Classification (HS 2017)</b>
zanidatamab	3002.13
zelminemab	3002.13
zelquistinel	2933.79
zildistrogene varoparovec	3002.90
ziltivekimab	3002.13
zorifertinib	2933.59

**Reclassification of INN products in HS 2022 edition (applicable as of 1.1.2022)**

RECLASSIFICATION (HS 2022) OF INN PRODUCTS (INN LIST 121)

<b>INN</b>	<b>Classification (HS 2022 edition)</b>
actinium ( <sup>225</sup> Ac) lintuzumab satetraxetan	2844.42
atleradstrocel	3002.51
betibeglogene autotemcel	3002.51
elivaldogene autotemcel	3002.51
firzotemcel	3002.51
flubrobenguane	2844.43
letetresgene autoleucel	3002.51
mipetresgene autoleucel	3002.51
olitresgene autoleucel	3002.51
omidubicel	3002.51
remestemcel	3002.51
rovaleucel	3002.51
setamevetcel	3002.51
stapuldencel	3002.51
tebrocabtogene autoleucel	3002.51